NEU neuren pharmaceuticals limited

From Growth factor shows promise for Phelan-McDermid syndrome...

  1. 2,136 Posts.
    lightbulb Created with Sketch. 61
    From Growth factor shows promise for Phelan-McDermid syndrome

    "Last week, a separate set of researchers announced that the drug appears to be safe and effective in a trial of 53 adolescents and adults with Rett syndrome."

    The inference is that IGF-1 was the drug being used instead of NNZ-2566. Only later on do you learn that:

    "The Rett trial uses a modified form of IGF-1 that includes only the first three amino acids, but which may induce production of the full-length form in the brain"


    I have noticed in a number of articles IGF-1 was being hyped and NNZ-2566 downplayed or not mentioned (as in the above announcement). To me IGF-1 is a competitor.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.88
Change
-0.140(1.00%)
Mkt cap ! $1.727B
Open High Low Value Volume
$13.90 $14.21 $13.64 $4.590M 329.8K

Buyers (Bids)

No. Vol. Price($)
1 600 $13.85
 

Sellers (Offers)

Price($) Vol. No.
$13.96 2894 1
View Market Depth
Last trade - 16.10pm 08/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.